Shiyu Wang Rejoins Qiming Venture Partners as Partner, Co-Leads TMT Team

SHANGHAI, Jan. 3, 2022 /PRNewswire/ — Qiming Venture Partners, a leading venture capital firm in China, is pleased to announce that Shiyu Wang has rejoined the firm as a Partner. Shiyu Wang will co-lead the TMT team, managing and investing in the internet and consumer sectors.

Shiyu Wang has many years of investment experience in the internet and consumer industries, having previously worked at Qiming Venture Partners from 2012 to 2016.

“I am honored to rejoin Qiming Venture Partners. I know Qiming very well, and identify very much with its culture. I have also personally experienced the respect and support that Qiming provides to the entrepreneurs,” Shiyu Wang said, “China is a world-class consumer country, and I believe there are still many opportunities and huge upgrade potential in the country’s consumer market in the next five to ten years. Qiming Venture Partners has excellent investment performances in mobile internet, especially in internet community and social networking. In the future, I hope that it can stay sharp and look for the new ‘big thing’ in the next wave of ‘network traffic change’.”

“I am very pleased to have Shiyu back in the Qiming family. I have worked with Shiyu for many years and appreciate his unique insights and successful experiences in the internet and consumer sectors. I very much look forward to working with Shiyu to lead our TMT team to discover more outstanding companies that will change the world and create value. Building on our success in healthcare and hardcore technology sectors over the past few years, Shiyu’s return will allow us to take another step forward in the internet and consumer sectors,” Duane Kuang, Founding Managing Partner of Qiming Venture Partners said.

From start-up to rapid growth, Qiming Venture Partners, as a venture capital firm in China, has gone through 15 years of history. Through the test of time, the company has been widely recognized by LP investors around the world, including China, for its exceptional investment performances, and has become a preferred investor of choice for entrepreneurs. Qiming Venture Partners has also been ranked as a leading fund in China’s venture capital industry by numerous agencies and publications.

Today, Qiming Venture Partners has developed a “being inclusive, staying hungry, keeping humility and sincerity” corporate culture, and its recognition and reputation continue to grow. With its unique partnership structure, focus on TMT and healthcare, as well as professional investment teams with strong industry background, Qiming Venture Partners is always committed to finding great companies for the future.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

Currently Qiming Venture Partners manages ten US Dollar funds and six RMB funds with $6.2 billion in AUM capital raised. Since our establishment, we have invested in outstanding companies in the TMT and healthcare industries at the early and growth stages.

Since our debut, we have backed over 430 fast-growing and innovative companies. Over 170 companies are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or achieved exit through M&A and other means. There are also over 40 portfolio companies that have achieved unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE: ZH), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), Venus MedTech (SEHK:2500), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), WeDoctor Group, and UBTech among many others.

SOURCE Qiming Venture Partners

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also
Back to top button